Opdivo

With Yervoy-beating data, Opdivo poised to fight melanoma's return after surgery
Fierce Pharma
Mon, 09/11/17 - 09:52 am
Yervoy
Opdivo
Bristol-Myers Squibb
melanoma
Opdivo combo shows early survival benefit in kidney cancer
BioPharma Dive
Fri, 09/8/17 - 09:34 am
Opdivo
Yervoy
Bristol-Myers Squibb
kidney cancer
FDA orders Bristol-Myers’ Opdivo to the sidelines on 3 studies as regulators explore dangers of checkpoint combos
Endpoints
Wed, 09/6/17 - 08:57 pm
FDA
Bristol-Myers Squibb
Opdivo
clinical trials
Multiple Myeloma
Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017
Market Realist
Fri, 08/18/17 - 12:14 pm
Opdivo
Bristol-Myers Squibb
Latest Immunotherapy Setback: Bristol Drugs Stumble in Kidney Cancer
Xconomy
Wed, 08/16/17 - 10:13 am
Bristol-Myers Squibb
kidney cancer
Opdivo
Yervoy
Forget BMY's Q2 Earnings, Watch Out For Opdivo Trials Going Forward
Forbes
Wed, 08/2/17 - 09:21 pm
Bristol-Myers Squibb
Opdivo
clinical trials
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Motley Fool
Wed, 08/2/17 - 09:18 am
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
Bristol-Myers Squibb's Opdivo nabs MSI-H colorectal cancer nod, but it can't match Keytruda's umbrella approval
Fierce Pharma
Tue, 08/1/17 - 11:10 am
Bristol-Myers Squibb
Opdivo
colorectal cancer
Merck
Keytruda
Bristol-Myers and Clovis will partner for cancer combination trials
Marketwatch
Mon, 07/31/17 - 10:07 am
clinical trials
Bristol-Myers Squibb
Clovis Oncology
Opdivo
Rubraca
Bristol shrugs off comparisons to MYSTIC
BioPharma Dive
Fri, 07/28/17 - 11:38 am
AstraZeneca
Bristol-Myers Squibb
Mystic
immuno-oncology
Opdivo
AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers
TheStreet.com
Thu, 07/27/17 - 11:07 am
AstraZeneca
clinical trials
Mystic
Bristol-Myers Squibb
Opdivo
FDA Considers Label Changes for Keytruda, Opdivo and Yervoy
RAPS.org
Wed, 07/12/17 - 02:41 pm
FDA
labeling
Keytruda
Opdivo
Yervoy
immuno-oncology
Merck
Bristol-Myers Squibb
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Yahoo/Zacks.com
Wed, 07/12/17 - 10:05 am
Exelixis
Bristol-Myers Squibb
clinical trials
Opdivo
Opdivo-Cabometyx
renal cell carcinoma
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now
Motley Fool
Mon, 07/10/17 - 11:34 pm
Celgene
Revlimid
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
AbbVie
JNJ
Imbruvica
Pfizer
Ibrance
cancer
Prescribed Reading: I/O is the only game in town
BioPharma Dive
Sat, 07/8/17 - 10:02 am
immuno-oncology
Celgene
BeiGene
Endo International
Opana ER
Novartis
Orkambi
Vertex Pharmaceuticals
Merck
Bristol-Myers Squibb
Roche
Opdivo
Keytruda
Orencia
Bristol Myers Vies to Be King of Immuno-Boosting Cancer Drugs with New Trial Update
TheStreet.com
Thu, 07/6/17 - 09:41 am
Bristol-Myers Squibb
Opdivo
melanoma
Bristol-Myers’ tarnished checkpoint star Opdivo beats out Yervoy in surprise PhIII
Endpoints
Wed, 07/5/17 - 10:00 am
Bristol-Myers Squibb
Opdivo
Yervoy
melanoma
Standing out in crowded cancer market
Medical Marketing and Media
Mon, 06/26/17 - 10:36 pm
cancer
Opdivo
Bristol-Myers Squibb
Is the Market Wrong About Bristol-Myers Squibb?
Motley Fool
Fri, 06/16/17 - 09:30 am
Bristol-Myers Squibb
Opdivo
Bristol-Myers Squibb: Still Too Many Uncertainties In The I/O Space
Seeking Alpha
Wed, 06/14/17 - 09:02 pm
Bristol-Myers Squibb
immuno-oncology
Opdivo

Pages